Edarbi: Clinical Trials

12 trials of Edarbi, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 1 terminated. 12 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 312Completed 11, Terminated 1

Follow Edarbi: new trials by email Literature Review of Edarbi trials Research Report on Edarbi

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
Losartan, Valsartan, Azilsartan - Covid19, SARS-CoV Infection
Phase 3TerminatedUniversity of British Columbia3412020-10-092023-02-16
Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
Azilsartan medoxomil, Valsartan, Azilsartan medoxomil Placebo - Essential Hypertension
Phase 3CompletedTakeda6122015-08-272019-03-05
A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
Azilsartan medoxomil/placebo, Azilsartan medoxomil - chlorthalidone - Essential Hypertension
Phase 3CompletedTakeda5072011-10-012014-04-23
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
Azilsartan medoxomil, Valsartan, Olmesartan - Hypertension
Phase 3CompletedTakeda12912008-04-012011-04-19
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension
Azilsartan medoxomil, Ramipril - Hypertension
Phase 3CompletedTakeda8852008-01-012012-11-15
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension
Azilsartan Medoxomil, Valsartan - Hypertension
Phase 3CompletedTakeda9842007-12-012012-02-02
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
Azilsartan Medoxomil and amlodipine, Amlodipine - Hypertension
Phase 3CompletedTakeda5662007-10-012011-07-22
Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension
Azilsartan medoxomil, Placebo - Hypertension
Phase 3CompletedTakeda4132007-10-012011-04-19
Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension
Azilsartan medoxomil and chlorthalidone, Chlorthalidone - Hypertension
Phase 3CompletedTakeda5512007-09-012011-04-19
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo - Hypertension
Phase 3CompletedTakeda4182007-06-012012-01-04
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide - Hypertension
Phase 3CompletedTakeda6692007-06-012011-04-19
Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
Azilsartan medoxomil and olmesartan, Olmesartan, Placebo - Hypertension
Phase 3CompletedTakeda12752007-06-012011-07-29

Conditions studied

Hypertension (10)  ·  Essential Hypertension (7)  ·  Cardiovascular Diseases (5)  ·  Acute Kidney Injury (1)  ·  COVID-19 (1)  ·  Coronavirus Infections (1)  ·  Respiratory Distress Syndrome (1)  ·  Severe Acute Respiratory Syndrome (1)  ·  Shock (1)  ·  Vascular Diseases (1)

Sponsors

Takeda (11)  ·  University of British Columbia (1)

Countries

United States (8)  ·  Mexico (5)  ·  Argentina (3)  ·  Bulgaria (2)  ·  Chile (2)  ·  Estonia (2)  ·  France (2)  ·  Germany (2)  ·  Netherlands (2)  ·  Peru (2)  ·  Poland (2)  ·  Puerto Rico (2)  ·  Serbia (2)  ·  Slovakia (2)  ·  Sweden (2)

Top investigators

James A Russell, MD (1)  ·  Karen Tran, MD (1)

Results publications

PMID 21282560, PMID 21272195, PMID 21762358, PMID 25619410, PMID 30175930, PMID 32769878, PMID 39325643